These autologous T cells are expanded ex vivo to recognize latent EBV antigens such as LMP1, LMP2, and EBNA1, and retain the ability to target tumor cells despite the restricted antigen profile of latency II [70]. This evidence concerns the gene PDLIM7 and neoplasm.